Skip to main content
FinSpry Logo
FinSpry
LIMN logo
LIMN
(NASDAQ)
Liminatus Pharma, Inc.
$0.19-- (--)
Loading... - Market loading
OverviewFinancialsForecastStatisticsDividendsHistoricalProfile

Liminatus Pharma (LIMN) Company Profile

Complete business overview, executive team, trading details, and corporate information.

Liminatus Pharma, Inc.
LIMN•Nasdaq Stock Market•Healthcare•Biotechnology

About Liminatus Pharma

Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPα blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOChris Kim
Founded2018
Employees1
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNasdaq Stock Market (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websiteliminatuspharma.com
Phone213 273 5453
Address
6 Centerpointe Drive, #625 La Palma, California 90623 United States

Corporate Identifiers

CIK0001831874
CUSIP53271X116
ISINUS53271X1081
SIC6770

Leadership Team & Key Executives

Chris Kim J.D., L.L.M.
Chief Executive Officer and Chairman
Scott Dam
Chief Financial Officer
Dr. Beom Kyu Choi
Chief Technology Officer and Member of Scientific Advisory Board
Dr. Byong Chul Yoo Ph.D.
Chief Science Officer and Member of Scientific Advisory Board
Dr. Sang-jin Lee Ph.D.
Head of Research and Development and Member of Scientific Advisory Board